Accordingly, a first-in-human phase 1 clinical study was conducted to evaluate DHES0815A as a single agent in patients with advanced and/or metastatic HER2+ BC for whom established treatment had proven ineffective. The gene discussed is ERBB2; the disease is breast cancer.